VERONA PHARMA PLC.
VRNA US9250501064
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-5% | 275% | -19% | 147% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Deschamps Lisa O |
13.14 USD |
9,464 Sold |
124,392 USD |
01/08/2025 | 01/08/2025 |
Hahn Mark W CFO |
13.14 USD |
208,912 Sold |
2,745,877 USD |
01/08/2025 | 01/08/2025 |
Edwards Martin O |
13.14 USD |
10,808 Sold |
142,057 USD |
01/08/2025 | 01/08/2025 |
Ackermann Christina O |
13.14 USD |
1,808 Sold |
23,764 USD |
01/08/2025 | 01/08/2025 |
Ebsworth David R O |
13.14 USD |
1,904 Sold |
25,026 USD |
01/08/2025 | 01/08/2025 |
Brady James Aloysius O |
13.14 USD |
824 Sold |
10,830 USD |
01/08/2025 | 01/08/2025 |
Cunningham Kenneth O |
13.14 USD |
10,808 Sold |
142,057 USD |
01/08/2025 | 01/08/2025 |
Fisher Andrew SR OFF |
13.14 USD |
9,584 Sold |
125,969 USD |
01/08/2025 | 01/08/2025 |
Zaccardelli David CEO |
13.14 USD |
208,912 Sold |
2,745,877 USD |
01/08/2025 | 01/08/2025 |
Sinha Vikas O |
13.14 USD |
4,328 Sold |
56,886 USD |
01/08/2025 | 01/08/2025 |